Summary:
Gastric antral vascular ectasia (GAVE) may occur after hematopoietic stem cell transplantation (HSCT) and cause severe and prolonged gastric bleeding. The underlying pathology of transplant-associated GAVE (HSCT-GAVE) is poorly understood and an effective therapeutic strategy has not been established yet. We retrospectively reviewed the medical records of 230 consecutive allogeneic transplant recipients in our institution between January 1997 and June 2002. We identified five patients who developed HSCT-GAVE (2.2%). Four patients had bleeding from HSCT-GAVE and one patient had HSCT-GAVE discovered incidentally. The clinical features of these patients were similar in that they all received conditioning treatment with busulfan and had history of thrombotic microangiopathy. Furthermore, treatment with a beta-blocker apparently improved the outcome of HSCT-GAVE in three patients. Bone Marrow Transplantation (2003) 32, 417-421. doi:10.1038/sj.bmt.1704137 Keywords: gastric antral vascular ectasia; hematopoietic stem cell transplantation; thrombotic microangiopathy; beta-blocker; busulfan Gastrointestinal complications are common following hematopoietic stem cell transplantation (HSCT); 1 however, gastric antral vascular ectasia (GAVE) is not well characterized in terms of its association with HSCT and only a few reports of GAVE in transplant recipients are available. HSCT-GAVE was first described by Marmaduke et al 2 in 10 patients who received allogeneic bone marrow transplantation. Although the incidence of HSCT-GAVE remains uncertain, bleeding, characterized as profuse and recurrent from hemorrhagic mucosa in the antrum, 3 occurs 20-90 days post-transplant. GAVE is diagnosed by the endoscopic appearance of gastric antrum and biopsies showing capillary dilation, thromboses, and fibromuscular hyperplasia. Tobin et al 3 reported that the male gender, busulfan containing conditioning regimens, and venoocclusive disease (VOD) of the liver, are correlated with the development of HSCT-GAVE, yet its etiology still remains obscure and standard treatment has not been established. In the present study, we retrospectively reviewed the clinical charts of 230 consecutive allogeneic transplant recipients for evidence of HSCT-GAVE.
Patients and methods
We retrospectively reviewed 230 patients (141 males, 89 females; median age 35 years, range 15-58) with hematological diseases who underwent allogeneic transplantation (201 bone marrow transplantations: 78 related, 123 unrelated; 25 related peripheral blood stem cell transplantations; four unrelated cord blood stem cell transplantations) in our institution between January 1997 and June 2002. Underlying diseases were chronic myeloid leukemia (n ¼ 60), acute nonlymphoid leukemia (n ¼ 65), acute lymphoid leukemia (n ¼ 56), myelodysplastic syndrome (n ¼ 22), severe aplastic anemia (n ¼ 11), non-Hodgkin's lymphoma (n ¼ 9), myelofibrosis (n ¼ 5), multiple myeloma (n ¼ 1), and Ewing's sarcoma (n ¼ 1). Preparative therapy was given basically according to the primary disease and type of transplant. Generally, patients with lymphoid malignancy were mainly conditioned with a total body irradiation (TBI, 12 Gy) containing regimen, including cytarabine (8 g/m 2 ) and cyclophosphamide (120 mg/kg). On the other hands, patients with myeloid malignancy were conditioned with a non-TBI containing regimen that included busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). Plasma concentration of busulfan was not monitored.
Results

Diagnosis of HSCT-GAVE
Of the 230 transplant recipients, 30 patients with signs of gastrointestinal symptoms underwent upper endoscopic examination and five patients (2.2%) were ultimately diagnosed with HSCT-GAVE, a median of 95 days (range, 65-208 days) after transplantation. All five patients received upper endoscopy on occasion of hematemesis (n ¼ 3), melena (n ¼ 1), or epigastric pain (n ¼ 1) (Table 1) . Two patients developed hypovolemic shock at the onset of GAVE. Diagnosis of HSCT-GAVE was based on the endoscopic appearance of red patches or spots in a diffuse array in the antrum of the stomach 5 ( Figure 1a ). Two patients (patient nos. 1 and 5) underwent endoscopic biopsy for histological diagnostic proof, which showed compatible pathological findings such as dilatation of mucosal capillaries with focal thrombosis and ectasia (Figure 1b and c). In three patients (patient nos. 2, 3, and 4), thrombocytopenia prevented us from obtaining endoscopic biopsy specimens; however, the obvious endoscopic characteristics of GAVE excluded the possibilities of antral ulceration, erosion, infection, or graft-versus-host disease.
Clinical feature of HSCT-GAVE
The patients' characteristics are shown in Table 2 . The group was composed by four males and one female with a median age of 51 years (range, 32-51 years). Their underlying diseases were CML (n ¼ 3), myelodysplastic syndrome (n ¼ 1), and acute myeloid leukemia (n ¼ 1). All were conditioned with a busulfan-containing regimen and received bone marrow from unrelated donors (n ¼ 4) or a related donor (n ¼ 1). The incidence of GAVE in patients with busulfan regimen (n ¼ 134) was higher than that in patients with non-busulfan regimen (n ¼ 96): five patients (3.7%) and zero patients (0%), respectively (P ¼ 0.0057). HSCT-GAVE has been associated with hepatic VOD; 2 however, in this group only patient no.1 had a prior VOD episode. Although one patient (patient no. 3) developed ascites 1 month before the onset of GAVE, his clinical symptoms did not meet the VOD criteria. 6 Rather, all patients exhibited the typical signs of thrombotic microangiopathy (TMA) 20-53 days (median 33 days) before the onset of GAVE (Table 2) . Clinical diagnosis of TMA was made by the presence of intravascular hemolysis in association with red cell fragmentation on the peripheral blood smear. Individual laboratory findings are shown in Table 2 . Elevated serum LDH with a decrease in hemoglobin and increased reticulocytes, as well as a drop in the platelet count, suggests the presence of microangiopathic hemolytic anemia.
Treatment of HSCT-GAVE
Effective treatment for patients with HSCT-GAVE has not been established as yet: the bleeding did not respond to omeprazole and platelet transfusion as in our cases (Table 1) . We initially pursued a therapeutic approach to reduce the symptoms because of complication of portal hypertension in one patient (patient no. 1). The patient underwent abdominal angiography during a bleeding episode, and the hepatic venous pressure gradient measured during procedure was approximately 13 mmHg. The diagnosis was HSCT-GAVE, rather than portal hypertensive gastropathy, due to the typical endoscopic appearance of diffuse red spots in the antrum but not in the fundus or corpus. She was administered the cardioselective betablocker metoprolol at 60 mg/day orally in three-divided doses. 7 A cardioselective beta-blocker was chosen because of her history of bronchial asthma. Her bleeding stopped or slowed appreciably within a couple of days due to the greatly reduced red blood cell transfusion requirement. Clinical features and treatment of HSCT-GAVE K Ohashi et al 
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Furthermore, metoprolol was tapered off without rebleeding approximately one month after the start of the therapy. This successful experience prompted us to treat the next two patients (patient nos. 2 and 3) with the same medication, even though they did not have obvious signs of portal hypertension. Surprisingly, both patients showed complete responses following treatment with the short-term beta-blocker; however, one patient (patient no. 2) developed rebleeding after the treatment was stopped, and then returned on up to 120 mg/day doses (Table 1) . He eventually died on day 236 due to pulmonary hemorrhage without further evidence of melena. All three patients experienced no major complication during a prescribed period. Thus, treatment with the short-term beta-blocker appears to have therapeutic potential, but is still questionable. Therefore, we evaluated an alternative therapeutic strategy, and two patients (patient nos. 4 and 5) underwent endoscopic ablation using argon plasma coagulation (APC) 8, 9 instead of receiving the short-term beta-blocker. One patient required repeated manipulations even though partial hemostasis was attained, suggesting the limitation of APC as a single therapeutic tool for HSCT-GAVE. The small number of patients treated prohibited further evaluation of the efficacy of this new strategy.
Discussion
The clinical features seen in our patients are mostly consistent with those reported in recent reviews, 2,3 and may propose several causal factors for the development of HSCT-GAVE. First, five (2.2%) of the 230 patients developed GAVE and all of our patients received oral busulfan for myeloablation. It is especially noteworthy that no cases of GAVE were observed in patients who conditioned with TBI regimen. The anatomic distribution of the GAVE lesions suggested direct mucosal damage from the oral administration of high-dose busulfan. 2 A variety of factors can cause intestinal dysfunction including stress, anxiety, some medications, and meal ingestion. 10 Thus, drugs orally given to hospitalized patients may retain in the proximal gut longer than in the distal gut, suggesting that the stomach and duodenum may be more extensively exposed to busulfan than the ileum and colon. This is the possible reason why the busulfan-related GAVE exclusively involves the stomach and proximal duodenum. It also suggests that vascular lesion is not limited to the gastric antrum, but vascular ectasia can extend into the duodenal bulb. In addition, we propose that high plasma concentrations of busulfan may contribute to the development of HSCT-GAVE. All of our patients developed severe mucositis immediately after busulfan administration (Table 2) , suggesting higher busulfan levels in patients with GAVE. 11, 12 Second, all of the patients had experienced a prior TMA episode and two patients developed ascites approximately 1 month before the onset of HSCT-GAVE. These potentially predisposing symptoms may reflect endothelial injury and local thrombosis, 13 and these events might be related to the pathogenesis of GAVE. Specially, local endothelial injury and subsequent local thrombosis may obstruct submucosal blood vessels and eventually lead to development of vascular ectasia. The fibrin thrombi and/or ectasia in mucosal vessels observed histologically in GAVE patients support this hypothesis. Third, although the pathological role of portal hypertension in the development of classical GAVE is controversial, 14 the documented case of portal hypertension and the efficacy of the beta-blocker observed in our patients suggests a possible association between portal hypertension and HSCT-GAVE.
In conclusion, five of the 230 patients who underwent HSCT developed GAVE at our institution. Development of GAVE may be associated with busulfan administration, endothelial injury, and portal hypertension. Treatment with a beta-blocker was well tolerated and all patients achieved a durable response. Although further study of this approach is warranted, beta-blocker therapy should be considered as a treatment for patients with HSCT-GAVE.
